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Abstract
Background: The physiological regulation of hepatic apoE gene has not been clarified, although the expression of
apoE in adipocytes and macrophages has been known to be regulated by LXR.
Methods and Results: We investigated the effect of TO901317, a LXR agonist, on hepatic apoE production
utilizing HepG2 cells cultured in spheroid form, known to be more differentiated than HepG2 cells in monolayer
culture. Spheroid HepG2 cells were prepared in alginate-beads. The secretions of albumin, apoE and apoA-I from
spheroid HepG2 cells were significantly increased compared to those from monolayer HepG2 cells, and these
increases were accompanied by increased mRNA levels of apoE and apoA-I. Several nuclear receptors including
LXRa also became abundant in nuclear fractions in spheroid HepG2 cells. Treatment with TO901317 significantly
increased apoE protein secretion from spheroid HepG2 cells, which was also associated with the increased
expression of apoE mRNA. Separation of the media with FPLC revealed that the production of apoE-rich large HDL
particles were enhanced even at low concentration of TO901317, and at higher concentration of TO901317,
production of VLDL particles increased as well.
Conclusions: LXR activation enhanced the expression of hepatic apoE, together with the alteration of lipoprotein
particles produced from the differentiated hepatocyte-derived cells. HepG2 spheroids might serve as a good model
of well-differentiated human hepatocytes for future investigations of hepatic lipid metabolism.
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Background
Apolipoprotein E (apoE), a 34-kD glycoprotein produced
mainly by hepatocytes and also secreted from several
cells including macrophages and adipocytes, plays a cru-
cial role in lipoprotein metabolism and atherosclerosis. It
mediates the cellular uptake of several classes of lipopro-
teins by acting as a ligand for the chylomicron remnant
receptor, the VLDL receptor, LDL receptor and the LDL
receptor-related protein (LRP). ApoE produced by macro-
phages and those accessing macrophages from the blood-
stream facilitate the reverse cholesterol transport
by promoting the formation and maturation of HDL
particles [1,2]. In addition to these functions, apoE pro-
duced in hepatocytes enhances the production of VLDL
particles [3]. The increased production of hepatic VLDL
particles, a phenomenon observed in insulin-resistant
patients or some primary hyperlipidemia subjects, leads
to the accumulation of atherogenic lipoproteins in the
circulation resulting in the aggravation of atherosclerosis.
The genetic regulation of the apoE gene has been pur-
sued extensively. Taylor et al has identified two hepatic
enhancer elements located far-downstream of the apoE
gene, and clarified the regions critical to the baseline
expression of the apoE gene [4,5]. They also identified
the duplicated downstream enhancer elements termed
multienhancers (ME.1 and ME.2), and demonstrated
that these elements are crucial for apoE expression in
macrophages and adipocytes [6]. In addition, Laffitte
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receptor (LXR) regulates apoE expression in adipocytes
and macrophages through direct interaction of the LXR
response element found in both ME.1 and ME.2 [7].
In spite of these extensive analyses on apoE gene regu-
lation, physiological factors which affect gene regulation
of apoE in the liver have not been elucidated so far. Pre-
vious in vivo studies utilizing guinea pig [8] and cebus
monkey [9] have shown that cholesterol feeding to these
animals resulted in the up-regulation of apoE gene in the
liver, raising the possibility that the accumulation of cho-
lesterol in hepatocytes would affect hepatic up-regulation
of the apoE gene. In addition, investigation in mice also
indicated the up-regulation of hepatic apoE gene by cho-
lesterol feeding [10]. However, the contribution of LXR
in the regulation of murine hepatic apoE was not demon-
strated [7,10]. Furthermore, no study has clarified the role
of LXR in the regulation of hepatic apoE gene in human-
derived hepatocytes or hepatic cell lines, with only one
exception which utilized artificial reporter gene construct,
in which ME.1 or ME.2 was placed just before the -890
to +93 apoE promoter [7].
As for the model of human hepatocytes, HepG2 cells
have been widely used for in vitro experiments; however
HepG2 cells grown in monolayer form on a culture
plate are different from the in vivo hepatocytes which
exist in three dimensional form in the liver, and would
not completely reflect the physiological functions of
hepatocytes. HepG2 cells in spheroid culture, which
grow in three dimensional form after being encapsulated
in alginate beads [11], have been shown to be more dif-
ferentiated than HepG2 cells cultured in monolayer
form; the cells proliferating in alginate beads form cell-
cell contact with each other, and normal hepato-cellular
junctional complexes including canaliculi with microvilli
are constructed [11]. In consequence, the production of
several proteins and the detoxificatory functions [11] as
well as the production of cholesterol and triglycerides
[12] increased significantly in HepG2 cells in spheroid
culture compared to those in monolayer culture.
In this report, we first compared the production of
several apolipoproteins from HepG2 cells in spheroid
culture with those in monolayer culture. Next, we exam-
ined the effect of TO901317, a synthetic LXR ligand, on
the secretion of apoE as well as lipoproteins with
HepG2 cells cultured both in three-dimensional form
and in monolayer form.
Results
HepG2 cells cultured in spheroid form (S-Hep) secreted
more albumin and apolipoproteins than HepG2 cells
cultured in monolayer (M-Hep)
HepG2 cells cultured in spheroid form grew in
three dimensional form (Figure 1A). To validate the
differentiation of HepG2 cells prepared as spheroids in
our procedure, we first examined the time-course
changes in the secretion of albumin. As shown in Figure
1B, the secretion of albumin from S-Hep was enhanced;
the highest secretion level was observed on Day 11,
reaching as high as 4.5-fold compared to M-Hep, which
was concordant with the previous report [11]. The
secretions of apolipoprotein A-I (apoA-I), apoE, and
apolipoprotein B (apoB) did also increase in S-Hep, and
the time-course changes in their levels were almost the
same as those found with albumin (Figure 1C-E). The
mRNA levels of apoA-I and apoE on Day 11 of S-Hep
revealed a 3-fold and 3.5-fold increase compared to M-
Hep (Figure 2A). Because the levels of albumin and
apoE secretions were highest on Day 11, for the subse-
quent experiments, we utilized S-Hep on Day 11.
PPAR-a, PPAR-g, LXR-a, RXR-a were more abundant in
the nuclear fractions of S-Hep than in those of M-Hep
In order to elucidate whether the up-regulation of the
genes of apolipoproteins in S-Hep were associated with
changes in the nuclear receptors, we next examined the
nuclear protein levels in S-Hep in comparison with M-
H e p .A ss h o w ni nF i g u r e2 Ba n d2 C ,t h eW e s t e r nb l o t
analyses of the proteins prepared from nuclear fractions
revealed that peroxisome proliferator-activated receptor
(PPAR)-a, LXR-a and retinoid × receptor (RXR)-a were
more abundant in S-Hep than M-Hep. We did not
observe differences in nuclear protein levels of hepato-
cyte nuclear factor (HNF)1-a and HNF4-a between
S-Hep and M-Hep, however, PPAR-g was also increased
in S-Hep. This result suggested that the state of differ-
entiation of hepatic deriv e dc e l l sw o u l da f f e c tt h e
expressions of several proteins associated with lipid
metabolism at the level of DNA transcription.
TO901317 increased apoE secretion and suppressed
apoA-I secretion from HepG2 spheroids more evidently
than monolayer HepG2 cells
The increased nuclear level of LXRa in S-Hep together
with the increased secretion of apoE from S-Hep
prompted us to evaluate the effect of LXRa agonist on
the secretion of apoE, because LXRa has been identified
as a critical factor for the regulation of apoE in macro-
phages and adipocytes. Thus we next examined the
effect of TO901317 (TO), a synthetic LXRa agonist, on
the apolipoproteins’ secretion from S-Hep as well as M-
Hep. As was shown in Figure 3A, the incubation of cells
with TO did not alter the levels of apoB secretion in
both S-Hep and M-Hep. The secretion of apoA-I was
decreased in both forms of HepG2 cells when the cells
were incubated with TO, which was concordant with
the previous finding by Huuskonen et al (Figure 3B)
[13]. On the other hand, apoE secretion was enhanced
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Page 2 of 11not only in S-Hep but also in M-Hep with the incuba-
tion of cells with TO (Figure 3C). The induction of
apoE in M-Hep plateaued at 0.02 μMT O ,w h i l et h e
dose-dependent increase in apoE secretion from S-Hep
was observed up to 0.2 μM. In addition, this incremental
apoE secretion was more prominent in S-Hep, reaching
almost twice the level of cells without TO.
TO901317 increased apoE and ABCA1 mRNA levels in
HepG2 spheroids
In order to evaluate whether the increased secretion of
apoE from S-Hep treated with TO was associated with
the upregulation of the apoE gene, we examined the
levels of apoE mRNA as well as ATP binding cassette
transporter (ABC) A1 mRNA with quantitative real time
PCR analyses. As shown in Figure 3D, the mRNA levels
of apoE were significantly elevated by TO treatment,
indicating that LXRa activated with TO would have
increased the transcription of apoE in S-Hep. ABCA1,
which is regulated by LXR, was also upregulated by
TO901317, although the levels of the induction were
less than those observed with apoE (Figure 3E).
Distribution of apoE secreted from S-Hep among
lipoproteins
As shown in the above experiments, we confirmed that
the secretion of apoE was enhanced in S-Hep compared
to M-Hep, and treatment of HepG2 cells with TO
resulted in the augmentation of apoE secretion from
HepG2 cells. We next analyzed the distributions of
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Figure 1 Differences in albumin and apolipoproteins secretion between monolayer and spheroid HepG2 cells. (A) Representative
appearance of HepG2 spheroids on Day 11. HepG2 spheroids were fixed with 10% formalin solution, and examined with confocal microscopy.
Briefly, from a single HepG2 cell, cells proliferate and form a spheroidal cell-cluster in an aliginate bead. (B-E) Time-course changes in the
secretion of albumin (B), apoA-I (C), apoE (D), and apoB (E) from S-Hep cells. S-Hep (spheroid HepG2 cells) were prepared and grown in alginate
beads as described in Materials and Methods, and the protein levels in the media on different time points after the beginning of the culture
were measured. X axes represent the days after the beginning of S-Hep culture. Data are mean ± SEM (n = 4). *: P < 0.01 compared with M-
Hep; †: P < 0.03 compared with M-Hep; ‡: P < 0.01 compared with M-Hep and P < 0.03 with S-Hep on the other time points.
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Page 3 of 11apoE, together with those of apoB and apoA-I, among
lipoproteins after fractionating the media with fast pro-
tein liquid chromatography (FPLC) which separated
lipoproteins depending on their sizes. The results are
shown in Figure 4 and 5: the fractions 21 - 26 corre-
sponded to VLDL, fractions 29 - 37 to LDL, and frac-
tions 38 - 48 to HDL based on the analysis of human
plasma (data not shown). Both in S-Hep and M-Hep,
apoA-I distribution was noted almost exclusively on
fractions corresponding to HDL fractions, especially
small HDL fractions; this distribution was not altered
even with TO treatment. ApoB proteins were detected
in fractions relevant to VLDL and LDL fractions,
although the apoBs found in VLDL were scarce. In addi-
tion, no difference was observed in the distribution
patterns of apoB between S-Hep and M-Hep, and treat-
ment with TO did not alter these patterns. In contrast,
unlike the findings of apoA-I and apoB, the distribution
of apoE on lipoproteins was affected not only by the
methods of the culture but also by the treatment with
TO. ApoE secreted from M-Hep, regardless of the treat-
ment with TO, were detected in the fractions spanning
between those of LDL and HDL, suggesting its distribu-
tion on large HDL fractions; in addition, no apoE band
was found in VLDL fractions even by the treatment
with TO. On the other hand, the culture of HepG2 cells
in spheroidal form rendered the apoE protein to reside
on normal-sized HDL particles. Interestingly, treatment
of S-Hep with TO not only increased the amount of
secreted apoE incrementally with the increment of the
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Figure 2 Differences in apolipoprotein mRNA and nuclear receptor protein levels among M-Hep and S-Hep. (A) Analyses of mRNA levels
of apoE and apoA-I with quantitative RT-PCR (n = 4). GAPDH mRNA was used as the endogenous control for the expression levels of the gene
of interest. (B, C) Western blot analyses were performed with the proteins prepared from nuclear fractions (Panel B), and nuclear protein levels
were quantified with Image J utilizing lamin A/C as the internal control (Panel C) (n = 3). Y-axes in panels A and C represent ratios to the data
of M-Hep.
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Figure 3 Effects of TO901317 treatment on the secretion and expression of apolipoproteins. (A-C) S-Hep and M-Hep were incubated
with different concentration of TO901317, and the levels of apoipoproteins secreted in the medium were analyzed. Panel A, B and C
represented apoB, apoA-I and apoE levels, respectively. (D, E) S-Hep were incubated with different concentration of TO901317, and mRNA levels
of apoE (D) and ABCA1 (E) were analyzed. Data are mean ± SEM (n = 4). X-axes represent the concentration of TO901317. *: P < 0.01 compared
with 0 μM, †: P < 0.05 with 0 μM, ‡: P < 0.01 with 0 and 0.02 μM, #: P < 0.03 with 0 and 0.02 μM.
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Figure 4 Effects of TO901317 treatment on the distribution of apolipoprotein among lipoproteins. Distribution of apoE (A), apoA-I (B),
and apoB (C) on lipoprotein particles in the medium harvested from S-Hep (left) and M-Hep (right). Following the fractionation of the media
with FPLC depending on the size of lipoproteins, fractionated samples were subjected to Western blot analyses or protein measurement with
ELISA kits. White circles, black circles, squares and triangles represent the results from the medium of cells incubated with 0 μM, 0.02 μM, 0.2 μM
and 2 μM of TO901317, respectively.
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Page 6 of 11dose of TO, but also rendered apoE to distribute on
fractions larger than normal HDL. Based on the obser-
vation that neither apoA-I nor apoB was detected in
these lipoprotein fractions, these fractions were assumed
to be large apoE rich HDL. Furthermore, TO treatment
of S-Hep resulted in the appearance of apoE on VLDL
fractions; the amount of apoE on VLDL increased incre-
mentally when the concentration of TO was increased
up to 2 μM. In addition, as shown in Figure 6, treatment
of S-Hep with 2 μM TO resulted in the increased trigly-
cerides levels in the fractions where apoE protein
increased with TO treatment. These results indicated
that the TO treatment not merely resulted in the
increased apoE protein levels in VLDL and large HDL
fractions, but also resulted in the increased particle
numbers and/or the enrichment of lipid content of
VLDL and large HDL particles.
Discussion
Utilization of primary hepatocytes or hepatocyte-derived
cell lines for in vitro experiments has helped us under-
stand the lipid metabolism in the liver. However, it has
been known that even the primary hepatocytes, when
cultured in monolayer form, lose their differentiated,
physiological functions quickly probably due to the loss
o fi t st h r e ed i m e n s i o n a li nv i v oc o n f o r m a t i o ni nt h e
experimental setting. In vivo experiments with rodents
have also enabled us to elucidate the lipid metabolism
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possess different properties from humans in lipid meta-
bolism. Thus, in this study, in order to overcome these
obstacles, we utilized 3-D spheroid culture system utiliz-
ing alginate beads, which has proven to be an easily-
manipulative tactic to reproduce hepatocytes or hepato-
cytes-derived cells similar to their natural, differentiated
in vivo counterparts.
Concordant with the previous observation by Khalil et
al. [11], we were able to demonstrate that the culture of
HepG2 cells in spheroid form resulted in enhanced
albumin secretion compared to that in monolayer form,
indicating that S-Hep utilized in this study had been
more differentiated than M-Hep. The secretions of
apoE, apoA-I, and apoB were also enhanced in S-Hep,
and the nuclear protein contents of PPAR-a, PPAR-g,
LXR-a and RXR-a were increased in S-Hep, indicating
that both of which are the features of differentiated
hepatocytes or hepatocyte-derived cells. Furthermore,
activation of LXR with TO901317 treatment of S-Hep
resulted in the increased secretion of apoE protein
which was accompanied by the up-regulation of apoE
mRNA levels. Taking into account the previous study
not showing a significant up-regulation of apoE gene
with M-Hep treated with LXR activation [7], we assume
that the differentiation of cells would be important to
clearly examine the regulation of apoE gene in hepato-
cytes or hepatocyte-derived cells with LXR agonist,
which is the case for macrophages and adipocytes [7].
The physiological regulation of apoE gene in the liver
has so far not been clarified, although the baseline
expression has been known to be controlled by distal
hepatic enhancer elements [4,5] as well as the proximal
promoter region to which TR4 orphan nuclear receptor
binds [14]. Laffitte et al suggested that apoE enhancers
and promoters containing LXRE would be important for
the activation of apoE promoter in M-Hep; however,
administration of LXR agonist in mice revealed a slight
but non-significant role of LXR in the regulation of
apoE in vivo [7]. Their observation does not depart at
all from our present study, considering that murine lipid
metabolism differs from that of humans in several
respects. It is also plausible that factors other than LXR
would regulate hepatic apoE gene in mice and probably
in humans, considering that the degree of up-regulation
of apoE gene observed in our study is less than those
found in adipocytes and macrophages [7]. Further stu-
dies are needed to clarify these factors, and we believe
that utilization of S-Hep would enable us to elucidate
these factors.
In this study, we also found that the increased apoE
secretion from S-Hep resulted in the alteration of
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Page 8 of 11lipoprotein classes produced from the cells. One of the
aspects of this alteration is the increased production of
VLDL particles. In the state of hepatic steatosis, not
only triglycerides but also cholesterol accumulate in
hepatocytes [15], and the oxidative stress which
increases in hepatic steatosis [16] transforms the choles-
terol to oxysterol, which is a natural ligand for LXR.
Because the production of apoE is one of the important
determinants for the secretion of VLDL or VLDL-TG
from the liver [3], the upregulation of apoE gene
together with the increased production of triglycerides
[17,18] by LXR activation facilitates the production of
VLDL particles, resulting in the atherogenic lipid profile
of the metabolic syndrome.
The other interesting finding in the alteration of lipo-
protein production from S-Hep with TO901317 treat-
ment was the increased production of large HDL
particles containing apoE. Treatment with TO901317
prevented atherosclerosis in various mouse models
[19-21], and increased apoE-rich HDL particles in
C57BL6 mice [22,23]. These reagent effects have been
attributed to the enhanced reverse cholesterol transport
from macrophages [24] through the up-regulation of
several key macrophagic proteins such as ABCA1 and
apoE [25,26]. However, in this study, we did indicate
that apoE-rich large HDL particles were also produced
from the differentiated hepatocyte-derived cells, and that
the induction was more pronounced with increasing
increments of LXR activation. Although apoE-rich HDL
has been speculated to play a role in delivering choles-
terol to hormone-producing tissues such as adrenal tis-
sues [27,28], several lines of study have indicated that
apoE-rich HDL would also play an important role in
reverse cholesterol transport; apoE-rich HDL is mainly
contained in large HDL and large HDL has been
demonstrated to extract cholesterol from macrophages
[29]. It was also suggested that apoE-containing HDL
efficiently enhanced cholesterol efflux [2,30]. Thus the
increased production of apoE-rich large HDL particles
from differentiated hepatocytes induced by LXR acti-
v a t i o nm i g h th a v ear o l ei nt h ep r o t e c t i o na g a i n s t
atherosclerosis.
Conclusions
In summary, by utilizing the differentiated spheroid
HepG2 cells, for the first time we were able to clearly
demonstrate that LXR activation resulted in the up-reg-
ulation of human hepatic apoE, which also enhanced
the production of VLDL particles and large apoE rich
HDL particles. In future studies, investigation using
HepG2 spheroids as surrogates to well-differentiated
human hepatocytes would serve well as a model to pre-
cisely understand lipid metabolism in the liver.
Methods
Cell Culture and Experimental Protocol
HepG2 cells, purchased from American Type Culture
Collection (ATCC, Manassas, VA), were cultured and
maintained in DMEM (Sigma-Aldrich Co. St. Louis,
MO) supplemented with 10% fetal bovine serum (FBS,
Gibco BRL, Eggstein, Germany) and 1% penicillin/strep-
tomycin (Gibco). For the experiment with M-Hep with-
out TO (Sigma-Aldrich), 24 hours prior to the harvest
of medium and cells, the medium was replaced with
FBS-free medium to eliminate the plasma proteins
derived from FBS in the medium. In the experimenta-
tion of M-Hep with TO, the medium was exchanged for
that containing various concentrations of TO dissolved
in DMSO at the cell confluency of around 70%. Two
days later, the medium was replaced with the FBS-free
medium containing the same concentration of TO, and
cells were incubated for another 24 hours prior to the
analysis. The collected cells were suspended in RIPA
buffer (Santa Cruz Biotechnology, Santa Cruz, CA) for
further analysis. The protein levels of the cell lysates
were measured with Lowry methods (BioRad, Hercules,
CA.) according to the manufacturer’s protocol.
S-Hep were prepared following the methods described
previously [11,12] with some modification. Briefly,
HepG2 cells cultured in monolayer were detached com-
pletely with Trypsin-EDTA (Gibco) and suspended in a-
MEM (Gibco) containing 10% FBS at the concentration
of 0.5 × 10
6/mL. The medium containing HepG2 cells
was mixed with the same amount of 2% alginate
(Sigma). The mixed solution was dropped into 0.102 M
CaCl2/0.15 M NaCl (pH 7.4) solution at the speed of 1.5
ml/min through a 23 G cannula equipped inside another
19 G cannula from which the air was ejected at the
speed of 1.2 L/min. This procedure yielded alginate-
beads containing HepG2 cells, whose diameters ranged
from 300 to 500 μm. The alginate beads were washed
with DMEM twice and cultured in DMEM supplemen-
ted with 10% FBS and 1% penicillin/streptomycin. Prior
to the harvest of cells and medium, beads containing S-
Hep were washed twice with DMEM and cultured in
FBS-containing DMEM with or without TO for two
days. Thereafter, the medium was exchanged with FBS-
free medium containing the same concentration of TO,
and the cells were incubated for another 24 hours. Then
the media were collected, and the cells were dissolved in
RIPA buffer after releasing them from alginate beads
with the incubation in PBS containing 4 mM EGTA
(pH 7.4) for 10 minutes.
Quantification of Secreted Proteins in Medium
The concentrations of albumin, apoA-I and apoB in the
media were measured by indirect sandwich enzyme-
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Page 9 of 11linked immunosorbent assay (ELISA) with human albu-
min ELISA quantification kit (Bethyl laboratories, Inc.
Montgomery, TX.) and ELISA kits for human apoA-I
and apoB (Mabtech Inc. Nacka Strand, Sweden). For
the quantification of apoE levels, the media, the
volumes of which were adjusted according to cell pro-
tein levels, were subjected to 10% SDS-PAGE followed
by Western-blot analysis with anti-apoE antibody
(Chemicon International Inc ,T e m e c u l a ,C A ) ,a n dt h e
intensities of the bands were measured by Image J
(from the NIH).
Preparation and Analysis of Nuclear Fraction
The nuclear fractions of HepG2 cells were obtained as
follows: cells were dissolved in Buffer A (10 mM
HEPES, 1.5 mM MgCl2,1 0m MK C l ,0 . 5m MD T T ,
0.05% NP40, protease inhibitor cocktail (Roche, Man-
nheim, Germany), pH7.9) and incubated on ice for 10
minutes, centrifuged at 900 g for 10 minutes. The pel-
lets were homogenized in Buffer B (5 mM HEPES. 1.5
mM MgCl2, 0.2 M EDTA, 0.5 mM DTT, 26% glycerol,
protease inhibitor cocktail, pH 7.9) supplemented with
NaCl to the final concentration of 300 mM. Then, the
solutions were centrifuged at 24,000 g for 20 minutes,
and the supernatants were analyzed as the nuclear
fractions of the cells. To quantify the levels of each
nuclear protein, 30 μg of nuclear proteins extracted as
above were subjected to 8% SDS-PGE followed by
Western blot analyses with anti-Lamin A/C, anti-
PPAR-a, anti-PPAR-g,a n t i - R X R - a, anti-LXR-a,a n t i -
HNF-1a,o ra n t i - H N F - 4 a antibody (Santa Cruz
Biotechnology).
Quantitative Real Time PCR
Total RNAs extracted from M-Hep and S-Hep with
GenElute mammalian total RNA miniprep kit (Sigma-
Aldrich) were subjected to reverse transcription with
Superscript II enzyme (Invitrogen Co. Carlsbad, CA).
Real-time quantitative PCR was performed with Light-
Cycler system (Roche Diagnostics Basel, Switzerland).
The expression levels of the gene of interest were nor-
malized to those of the endogenous control GAPDH
mRNA, and the amounts of target gene expressions
w e r ee x p r e s s e da sar a t i ot ot hose of control cells. The
following primers were used: for GAPDH, forward 5’
CCACTCCTCCACCTTTGA 3’ and reverse 5’ GTG
GTCCAGGGGTCTTAC 3’;f o ra p o A - I ,f o r w a r d5 ’
TGTCCCAGTTTGAAGGCT 3’ and reverse 5’ ATCC
TTGCTCATCTCCTGC 3’; for apoE, forward 5’ GGGT
CGCTTTTGGGATTAC 3’ and reverse 5’ CAACT
CCTTCATGGTCTCG 3’; for ABCA1, forward 5’
AAATCCATTGTGGCTGC 3’ and reverse 5’ GGGA-
GAGAGAGGTTGTGATAC 3’.
FPLC Analysis
The media of S-Hep or M-Hep, the total volumes of
which were 12 mL, were concentrated to about 500 μl
by centrifugation through Amicon Ultara-15 (Millipore
Co., Bedford, MA). Then 200 μl of concentrated med-
ium was separated by FPLC utilizing Superose 6 col-
umn. The levels of apoB in the separated fractions were
analysed with ELISA method. For the analyses of apoE
and apoA-I, the separated fractions were subjected to
Western blots utilizing anti-apoE antibody and anti-
apoA-I antibody (Chemicon). To raise the sensitivity of
western blot analysis, after the incubation with primary
antibodies, the membranes were incubated in biotin-
conjugated anti-goat IgG antibody (Sigma) and then
detected by Vecstatin ABC kit (Vector laboratories, Inc,
B u r l i n g a m e ,C A ) .F P L Cf r actions obtained from S-Hep
with or without 2 μM TO were subjected to the mea-
surement of triglycerides (TG) levels with enzymatic
method (WAKO Pure Chemical Industries, Osaka,
Japan). To standardize the TG values among samples
from with or without TO, the values obtained were
adjusted utilizing the TG levels of the media which was
corrected with cellular protein levels.
Statistical analysis
The results were expressed as mean ± SEM. Differences
between two groups were evaluated with student’s t-test,
and the differences among more than assessed with
o n e - w a yA N O V A ,f o l l o w e db ym u l t i p l ec o m p a r i s o n
tests. the P value less than 0.05 was deemed as statisti-
cally significant.
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